

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete in ink	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		10/54146	
Date Submitted: July 6, 2005 <i>(use as many sheets as necessary)</i>		Application Number	Unassigned
		Filing Date	July 6, 2005
		First Named Inventor	Peter HUDSON
		Group Art Unit	Unassigned 1624
		Examiner Name	Unassigned COLEMAN
Sheet	1	of	1
		Attorney Docket Number	023234-0106

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T6
BC	A5	International Search Report of PCT/EP2004/001304.	

Examiner Signature	Brenda Coleman	Date Considered	April 1, 2007
-----------------------	----------------	--------------------	---------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**BEST AVAILABLE COPY**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>Date Submitted: March 6, 2006 (use as many sheets as necessary)</p>				<p><i>Complete if Known</i></p>	
Sheet	1	of	2	Application Number	10/541,460
				Filing Date	March 6, 2006
				First Named Inventor	Peter HUDSON
				Group Art Unit	Unassigned 1634
				Examiner Name	Unassigned COLEMAN
				Attorney Docket Number	052209-0138

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

## U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document		Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number	Kind Code <sup>2</sup> (if known)			

## FOREIGN PATENT DOCUMENTS

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T6
BC	B1	Thomas BOSSMAR et al., "Effects of SR 49059, an orally active V <sub>1a</sub> vasopressin receptor antagonist, on vasopressin-induced uterine contractions", British Journal of Obstetrics & Gynaecology, April 1997, Vol. 104, pp. 471-477.	
BC	B2	R. BROUARD et al., "Effect of SR49059 an orally active V <sub>1a</sub> vasopressin receptor antagonist, in the prevention of dysmenorrhoea", British Journal of Obstetrics & Gynaecology , May 2000, Vol. 107, pp. 614-619.	
BC	B3	Venkatesan ARANAPAKAM et al., '4,10-DIHYDRO-5H-THIENO[3,2-c][1]BENZAZEPINE DERIVATIVES AND 9,10-DIHYDRO-4H-THIENO[2,3-c][1]BENZAZEPINE DERIVATIVES AS ORALLY ACTIVE ARGININE VASOPRESSIN RECEPTOR AGONISTS", Bioorganic & Medicinal Chemistry Letters 9 (1999) pp. 1733-1736.	
BC	B4	M. ARTICO et al., "RICERCHE SU SOSTANZE AD ATTIVITA ANTIBLASTICA", Il Fármaco, Ed. Sc. Vol. 24, no. 3, pp. 276-284, Mar. 1969	
BC	B5	F. CHIMENTI et al., "RICERCHE SU SOSTANZE AD ATTIVITA ANTIBLASTICA", Il Fármaco, Ed. Sc. Vol. 32, no. 5, pp. 339-347, May 1977	

Examiner Signature	Brenda Coleman	Date Considered	April 1, 2007
--------------------	----------------	-----------------	---------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/541,460
Date Submitted: March 6, 2006 (use as many sheets as necessary)				Filing Date	March 6, 2006
Sheet	2	of	2	First Named Inventor	Peter HUDSON
				Group Art Unit	Unassigned 1624
				Examiner Name	Unassigned COLEMAN
				Attorney Docket Number	052209-0138

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
BC	B6	Jiban K. CHAKRABARTI et al., "4-piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as Potential Neuroleptics", J. Med. Chem. 1980, 23, pp. 878-884.	
BC	B7	Jiban K. CHARABARTI et al., "10-Piperazinyl-4H-thieno[3,2-b][1,5]- and -[3,4-b][1,5]benzodiazepines as Potential Neuroleptics", J. Med. Chem. 1980, 23, pp. 884-889.	
BC	B8	Jiban K. CHARABARTI et al., "Synthesis and Pharmacological Evaluation of a Series of 4-Piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as Potential Anxiolytics", J. Med. Chem. 1989, 32, pp. 2573-2582.	
BC	B9	Alba CHIMIRRI et al., "ANNELATED 1,5-BENZODIAZEPINES. PART I. THREE, FOUR, AND FIVE MEMBERED RINGS", HETEROCYCLES, VOL. 36, NO. 3, 1993, PP. 601-637.	
BC	B10	Gary L. GUNEWALD et al., "Effect of Ring Size or an Additional Heteroatom on the Potency and Selectivity of Bicyclic Benzylamine-Type Inhibitors of Phenylethanolamine N-Methyltransferase", J. MED. CHEM. 1996, 39, 3539-3546.	
BC	B11	Janice M. KLUNDER et al., "Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 2. Tricyclic Pyridobenzoxazepinones and Dibenzoxazepinones", J. Med. Chem., 1992, 35, pp. 1887-1897.	
BC	B12	Jean-Françoise F. LIÉGEOIS et al., "Pyridobenzoxazepine and Pyridobenzothiazepine Derivates as Potential Central Nervous System Agents: Synthesis and Neurochemical Study", J. Med. Chem. 1994, 37;pp. 519-525.	
BC	B13	Timothy O. OLAGBEMIRO et al., "Alkylation and an Unusual Reductive Ring Opening of Some Thieno[3,4-b][1,5]benzoxazepin-10-ones", Department of Chemistry, Bayero University, Kano, Nigeria, VOL 19, NOV-DEC 1982, pp. 1501-1504	
BC	B14	William B. WRIGHT Jr. et al., "Derivatives of 11-(1-Piperazinyl)-5H-pyrido[2,1-c][1,4]benzodiazepine as Central Nervous Systems Agents", J. Med. Chem. 1980, 23, pp. 462-465.	
BC	B15	Satoru SASATANI et al., "DIISOBUTYLALUMINUM HYDRIDE A NOVEL REAGENT FOR THE REDUCTION OF OXIMES", Tetrahedron Letters, Vol. 24, No. 43, pp. 4711-4712, 1983.	

\*\* structures only

Examiner Signature	Brenda Coleman	Date Considered	April 1, 2007
--------------------	----------------	-----------------	---------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.